BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pon JR, Marra MA. Driver and Passenger Mutations in Cancer. Annu Rev Pathol Mech Dis 2015;10:25-50. [DOI: 10.1146/annurev-pathol-012414-040312] [Cited by in Crossref: 169] [Cited by in F6Publishing: 126] [Article Influence: 24.1] [Reference Citation Analysis]
Number Citing Articles
1 Luen S, Virassamy B, Savas P, Salgado R, Loi S. The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016;29:241-250. [PMID: 27481651 DOI: 10.1016/j.breast.2016.07.015] [Cited by in Crossref: 104] [Cited by in F6Publishing: 93] [Article Influence: 20.8] [Reference Citation Analysis]
2 Zhang H, Qin C, An C, Zheng X, Wen S, Chen W, Liu X, Lv Z, Yang P, Xu W, Gao W, Wu Y. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer 2021;20:126. [PMID: 34598686 DOI: 10.1186/s12943-021-01431-6] [Reference Citation Analysis]
3 Ding XX, Zhu QG, Zhang SM, Guan L, Li T, Zhang L, Wang SY, Ren WL, Chen XM, Zhao J, Lin S, Liu ZZ, Bai YX, He B, Zhang HQ. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget. 2017;8:55715-55730. [PMID: 28903454 DOI: 10.18632/oncotarget.18382] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
4 Avramović V, Frederiksen SD, Brkić M, Tarailo-Graovac M. Driving mosaicism: somatic variants in reference population databases and effect on variant interpretation in rare genetic disease. Hum Genomics 2021;15:71. [PMID: 34906245 DOI: 10.1186/s40246-021-00371-y] [Reference Citation Analysis]
5 Chandana SR, Babiker HM, Mahadevan D. Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics. Expert Opin Investig Drugs 2020;29:1413-29. [PMID: 33074030 DOI: 10.1080/13543784.2020.1838484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hu W, Yang Y, Ge W, Zheng S. Deciphering molecular properties of hypermutated gastrointestinal cancer. J Cell Mol Med 2019;23:370-9. [PMID: 30381870 DOI: 10.1111/jcmm.13941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
7 Pavlenko E, Cabron AS, Arnold P, Dobert JP, Rose-John S, Zunke F. Functional Characterization of Colon Cancer-Associated Mutations in ADAM17: Modifications in the Pro-Domain Interfere with Trafficking and Maturation. Int J Mol Sci 2019;20:E2198. [PMID: 31060243 DOI: 10.3390/ijms20092198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 McDonell LM, Kernohan KD, Boycott KM, Sawyer SL. Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin. Hum Mol Genet 2015;24:R60-6. [PMID: 26152202 DOI: 10.1093/hmg/ddv254] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
9 Burns MB, Blekhman R. Integrating tumor genomics into studies of the microbiome in colorectal cancer. Gut Microbes 2019;10:547-52. [PMID: 30556775 DOI: 10.1080/19490976.2018.1549421] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
10 Nussinov R, Tsai CJ, Jang H. Why Are Some Driver Mutations Rare? Trends Pharmacol Sci 2019;40:919-29. [PMID: 31699406 DOI: 10.1016/j.tips.2019.10.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
11 Mroz EA, Rocco JW. The challenges of tumor genetic diversity. Cancer 2017;123:917-27. [PMID: 27861749 DOI: 10.1002/cncr.30430] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
12 Lange M, Begolli R, Giakountis A. Non-Coding Variants in Cancer: Mechanistic Insights and Clinical Potential for Personalized Medicine. Noncoding RNA 2021;7:47. [PMID: 34449663 DOI: 10.3390/ncrna7030047] [Reference Citation Analysis]
13 Gorlov IP, Gorlova OY, Amos CI. Untouchable genes in the human genome: Identifying ideal targets for cancer treatment. Cancer Genet 2019;231-232:67-79. [PMID: 30803560 DOI: 10.1016/j.cancergen.2019.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Piraino SW, Furney SJ. Beyond the exome: the role of non-coding somatic mutations in cancer. Ann Oncol 2016;27:240-8. [PMID: 26598542 DOI: 10.1093/annonc/mdv561] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
15 Wei T, Fa B, Luo C, Johnston L, Zhang Y, Yu Z. An Efficient and Easy-to-Use Network-Based Integrative Method of Multi-Omics Data for Cancer Genes Discovery. Front Genet 2020;11:613033. [PMID: 33488678 DOI: 10.3389/fgene.2020.613033] [Reference Citation Analysis]
16 Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: An update and perspective. Drug Resist Updat 2021;:100796. [PMID: 34953682 DOI: 10.1016/j.drup.2021.100796] [Reference Citation Analysis]
17 Koschmann C, Nunez FJ, Mendez F, Brosnan-Cashman JA, Meeker AK, Lowenstein PR, Castro MG. Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer. Cancer Res 2017;77:227-33. [PMID: 28062403 DOI: 10.1158/0008-5472.CAN-16-2301] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
18 Lennartz M, Gehrig E, Weidemann S, Gorbokon N, Menz A, Büscheck F, Hube-magg C, Hinsch A, Reiswich V, Höflmayer D, Fraune C, Jacobsen F, Bernreuther C, Lebok P, Sauter G, Wilczak W, Steurer S, Burandt E, Marx AH, Simon R, Krech T, Clauditz TS, Minner S, Dum D, Uhlig R. Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma. Diagnostics 2021;11:2351. [DOI: 10.3390/diagnostics11122351] [Reference Citation Analysis]
19 Gorlov IP, Xia X, Tsavachidis S, Gorlova OY, Amos CI. Tumor somatic mutations also existing as germline polymorphisms may help to identify functional SNPs from genome-wide association studies. Carcinogenesis 2020;41:1353-62. [PMID: 32681635 DOI: 10.1093/carcin/bgaa077] [Reference Citation Analysis]
20 Gregoire-Mitha S, Gray DA. What deubiquitinating enzymes, oncogenes, and tumor suppressors actually do: Are current assumptions supported by patient outcomes? Bioessays 2021;43:e2000269. [PMID: 33415735 DOI: 10.1002/bies.202000269] [Reference Citation Analysis]
21 Ishida Y. PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond. Cells 2020;9:E1376. [PMID: 32492969 DOI: 10.3390/cells9061376] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
22 Mueller FB. AI (Artificial Intelligence) and Hypertension Research. Curr Hypertens Rep 2020;22:70. [PMID: 32852654 DOI: 10.1007/s11906-020-01068-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Li J, Hu K, Zhou L, Huang J, Zeng S, Xu Z, Yan Y. Spectrum of Mesenchymal-Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis. Front Oncol 2020;10:560615. [PMID: 33178590 DOI: 10.3389/fonc.2020.560615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Jia D, Xing Y, Zhan Y, Cao M, Tian F, Fan W, Huang J, Cui Y, Gu R, Cui Y, Liu Y, Zhang S, Cai L, Li X. LINC02678 as a Novel Prognostic Marker Promotes Aggressive Non-small-cell Lung Cancer. Front Cell Dev Biol 2021;9:686975. [PMID: 34124072 DOI: 10.3389/fcell.2021.686975] [Reference Citation Analysis]
25 Liang ZZ, Zhu RM, Li YL, Jiang HM, Li RB, Tang LY, Wang Q, Ren ZF. Differential epigenetic and transcriptional profile in MCF-7 breast cancer cells exposed to cadmium. Chemosphere 2020;261:128148. [PMID: 33113665 DOI: 10.1016/j.chemosphere.2020.128148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Ciomborowska-Basheer J, Staszak K, Kubiak MR, Makałowska I. Not So Dead Genes-Retrocopies as Regulators of Their Disease-Related Progenitors and Hosts. Cells 2021;10:912. [PMID: 33921034 DOI: 10.3390/cells10040912] [Reference Citation Analysis]
27 Zhou W, Zhao Z, Wang R, Han Y, Wang C, Yang F, Han Y, Liang H, Qi L, Wang C, Guo Z, Gu Y. Identification of driver copy number alterations in diverse cancer types and application in drug repositioning. Mol Oncol 2017;11:1459-74. [PMID: 28719033 DOI: 10.1002/1878-0261.12112] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
28 Belikov AV. Age-related diseases as vicious cycles. Ageing Res Rev 2019;49:11-26. [PMID: 30458244 DOI: 10.1016/j.arr.2018.11.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
29 Zheng X, Zhang G, Li P, Zhang M, Yan X, Zhang X, Yang J, Li H, Liu X, Ma Z, Wang H. Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib. Lung Cancer 2019;129:72-4. [PMID: 30797494 DOI: 10.1016/j.lungcan.2019.01.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
30 Juul M, Madsen T, Guo Q, Bertl J, Hobolth A, Kellis M, Pedersen JS. ncdDetect2: improved models of the site-specific mutation rate in cancer and driver detection with robust significance evaluation. Bioinformatics 2019;35:189-99. [PMID: 29945188 DOI: 10.1093/bioinformatics/bty511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Clayton EA, Wang L, Rishishwar L, Wang J, McDonald JF, Jordan IK. Patterns of Transposable Element Expression and Insertion in Cancer. Front Mol Biosci 2016;3:76. [PMID: 27900322 DOI: 10.3389/fmolb.2016.00076] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
32 Biancolella M, Testa B, Baghernajad Salehi L, D'Apice MR, Novelli G. Genetics and Genomics of Breast Cancer: update and translational perspectives. Semin Cancer Biol 2021;72:27-35. [PMID: 32259642 DOI: 10.1016/j.semcancer.2020.03.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Wuputra K, Ku CC, Wu DC, Lin YC, Saito S, Yokoyama KK. Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells. J Exp Clin Cancer Res 2020;39:100. [PMID: 32493501 DOI: 10.1186/s13046-020-01584-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Zou X, Owusu M, Harris R, Jackson SP, Loizou JI, Nik-Zainal S. Validating the concept of mutational signatures with isogenic cell models. Nat Commun 2018;9:1744. [PMID: 29717121 DOI: 10.1038/s41467-018-04052-8] [Cited by in Crossref: 71] [Cited by in F6Publishing: 54] [Article Influence: 17.8] [Reference Citation Analysis]
35 Satpathy M, Mezencev R, Wang L, McDonald JF. Targeted in vivo delivery of EGFR siRNA inhibits ovarian cancer growth and enhances drug sensitivity. Sci Rep 2016;6:36518. [PMID: 27819259 DOI: 10.1038/srep36518] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
36 Hao Q, Wei P, Shu Y, Zhang YG, Xu H, Zhao JN. Improvement of Neoantigen Identification Through Convolution Neural Network. Front Immunol 2021;12:682103. [PMID: 34113354 DOI: 10.3389/fimmu.2021.682103] [Reference Citation Analysis]
37 Laham-Karam N, Pinto GP, Poso A, Kokkonen P. Transcription and Translation Inhibitors in Cancer Treatment. Front Chem 2020;8:276. [PMID: 32373584 DOI: 10.3389/fchem.2020.00276] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
38 Mohsen H, Gunasekharan V, Qing T, Seay M, Surovtseva Y, Negahban S, Szallasi Z, Pusztai L, Gerstein MB. Network propagation-based prioritization of long tail genes in 17 cancer types. Genome Biol 2021;22:287. [PMID: 34620211 DOI: 10.1186/s13059-021-02504-x] [Reference Citation Analysis]
39 Aksenova AY, Zhuk AS, Lada AG, Zotova IV, Stepchenkova EI, Kostroma II, Gritsaev SV, Pavlov YI. Genome Instability in Multiple Myeloma: Facts and Factors. Cancers (Basel) 2021;13:5949. [PMID: 34885058 DOI: 10.3390/cancers13235949] [Reference Citation Analysis]
40 Melloy PG. The anaphase-promoting complex: A key mitotic regulator associated with somatic mutations occurring in cancer. Genes Chromosomes Cancer 2020;59:189-202. [PMID: 31652364 DOI: 10.1002/gcc.22820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
41 Piaggio F, Tozzo V, Bernardi C, Croce M, Puzone R, Viaggi S, Patrone S, Barla A, Coviello D, Jager MJ, van der Velden PA, Zeschnigk M, Cangelosi D, Eva A, Pfeffer U, Amaro A. Secondary Somatic Mutations in G-Protein-Related Pathways and Mutation Signatures in Uveal Melanoma. Cancers (Basel) 2019;11:E1688. [PMID: 31671564 DOI: 10.3390/cancers11111688] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
42 Bacher U, Shumilov E, Flach J, Porret N, Joncourt R, Wiedemann G, Fiedler M, Novak U, Amstutz U, Pabst T. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. Blood Cancer J 2018;8:113. [PMID: 30420667 DOI: 10.1038/s41408-018-0148-6] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 14.0] [Reference Citation Analysis]
43 Tod BM, Schneider JW, Bowcock AM, Visser WI, Kotze MJ. The tumor genetics of acral melanoma: What should a dermatologist know? JAAD Int 2020;1:135-47. [PMID: 34355205 DOI: 10.1016/j.jdin.2020.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
44 Bokhari Y, Arodz T. QuaDMutEx: quadratic driver mutation explorer. BMC Bioinformatics 2017;18:458. [PMID: 29065872 DOI: 10.1186/s12859-017-1869-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
45 Qu J, Mei Q, Liu L, Cheng T, Wang P, Chen L, Zhou J. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer. Ther Adv Med Oncol 2021;13:1758835921992968. [PMID: 33643442 DOI: 10.1177/1758835921992968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
46 Bii VM, Trobridge GD. Identifying Cancer Driver Genes Using Replication-Incompetent Retroviral Vectors. Cancers (Basel) 2016;8:E99. [PMID: 27792127 DOI: 10.3390/cancers8110099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
47 Rajendran BK, Deng CX. Characterization of potential driver mutations involved in human breast cancer by computational approaches. Oncotarget 2017;8:50252-72. [PMID: 28477017 DOI: 10.18632/oncotarget.17225] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
48 Raimondi F, Russell RB. Studying how genetic variants affect mechanism in biological systems. Essays Biochem 2018;62:575-82. [PMID: 30315099 DOI: 10.1042/EBC20180021] [Reference Citation Analysis]
49 Vitale I, Sistigu A, Manic G, Rudqvist NP, Trajanoski Z, Galluzzi L. Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends Cell Biol 2019;29:396-416. [PMID: 30765144 DOI: 10.1016/j.tcb.2019.01.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 12.3] [Reference Citation Analysis]
50 Hao Y, He L, Zhou Y, Zhao Y, Li M, Jing R, Wen Z. Improving Model Performance on the Stratification of Breast Cancer Patients by Integrating Multiscale Genomic Features. Biomed Res Int 2020;2020:1475368. [PMID: 32908867 DOI: 10.1155/2020/1475368] [Reference Citation Analysis]
51 Lavrentovich MO, Nelson DR. Nucleation of antagonistic organisms and cellular competitions on curved, inflating substrates. Phys Rev E 2019;100. [DOI: 10.1103/physreve.100.042406] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
52 Oršolić I, Bursać S, Jurada D, Drmić Hofman I, Dembić Z, Bartek J, Mihalek I, Volarević S. Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint. Oncogene 2020;39:3443-57. [PMID: 32108164 DOI: 10.1038/s41388-020-1231-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
53 Sugai T, Eizuka M, Takahashi Y, Fukagawa T, Habano W, Yamamoto E, Akasaka R, Otuska K, Matsumoto T, Suzuki H. Molecular subtypes of colorectal cancers determined by PCR-based analysis. Cancer Sci 2017;108:427-34. [PMID: 28083970 DOI: 10.1111/cas.13164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
54 Jiang Y, Liu L, Shan W, Yang ZQ. An integrated genomic analysis of Tudor domain-containing proteins identifies PHD finger protein 20-like 1 (PHF20L1) as a candidate oncogene in breast cancer. Mol Oncol 2016;10:292-302. [PMID: 26588862 DOI: 10.1016/j.molonc.2015.10.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
55 Sayed S, Paszkowski-Rogacz M, Schmitt LT, Buchholz F. CRISPR/Cas9 as a tool to dissect cancer mutations. Methods 2019;164-165:36-48. [PMID: 31078796 DOI: 10.1016/j.ymeth.2019.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Wang Y, Xue H, Pourcel C, Du Y, Gautheret D. 2-kupl: mapping-free variant detection from DNA-seq data of matched samples. BMC Bioinformatics 2021;22:304. [PMID: 34090332 DOI: 10.1186/s12859-021-04185-6] [Reference Citation Analysis]
57 Sadeghi Rad H, Monkman J, Warkiani ME, Ladwa R, O'Byrne K, Rezaei N, Kulasinghe A. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev 2021;41:1474-98. [PMID: 33277742 DOI: 10.1002/med.21765] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
58 Galassi C, Manic G, Musella M, Sistigu A, Vitale I. Assessment of IFN-γ and granzyme-B production by in "sitro" technology. Methods Enzymol 2020;631:391-414. [PMID: 31948559 DOI: 10.1016/bs.mie.2019.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Seetharaman S, Flemyng E, Shen J, Conte MR, Ridley AJ. The RNA-binding protein LARP4 regulates cancer cell migration and invasion. Cytoskeleton (Hoboken) 2016;73:680-90. [PMID: 27615744 DOI: 10.1002/cm.21336] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
60 Andrieux G, Chakraborty S. Editorial: Integration of Multi-Omics Techniques in Cancer. Front Genet 2021;12:733965. [PMID: 34434225 DOI: 10.3389/fgene.2021.733965] [Reference Citation Analysis]
61 Hu W, Li X, Wang T, Zheng S. Association mining of mutated cancer genes in different clinical stages across 11 cancer types. Oncotarget 2016;7:68270-7. [PMID: 27556693 DOI: 10.18632/oncotarget.11392] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
62 Liu G, Liu G, Cui X, Xu Y. Transcriptomic Data Analyses Reveal a Reprogramed Lipid Metabolism in HCV-Derived Hepatocellular Cancer. Front Cell Dev Biol 2020;8:581863. [PMID: 33195224 DOI: 10.3389/fcell.2020.581863] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Islam SMA, Alexandrov LB. Bioinformatic Methods to Identify Mutational Signatures in Cancer. Methods Mol Biol 2021;2185:447-73. [PMID: 33165866 DOI: 10.1007/978-1-0716-0810-4_28] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Henikoff S. Mechanisms of Nucleosome Dynamics In Vivo. Cold Spring Harb Perspect Med 2016;6:a026666. [PMID: 27503998 DOI: 10.1101/cshperspect.a026666] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
65 Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin 2020;70:125-37. [PMID: 32031692 DOI: 10.3322/caac.21600] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
66 Hahn MM, de Voer RM, Hoogerbrugge N, Ligtenberg MJ, Kuiper RP, van Kessel AG. The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery. Cell Oncol (Dordr) 2016;39:491-510. [PMID: 27279102 DOI: 10.1007/s13402-016-0284-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
67 Yamulla RJ, Nalubola S, Flesken-Nikitin A, Nikitin AY, Schimenti JC. Most Commonly Mutated Genes in High-Grade Serous Ovarian Carcinoma Are Nonessential for Ovarian Surface Epithelial Stem Cell Transformation. Cell Rep 2020;32:108086. [PMID: 32877668 DOI: 10.1016/j.celrep.2020.108086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
68 Zhao J, Sun Y, Huang Y, Song F, Huang Z, Bao Y, Zuo J, Saffen D, Shao Z, Liu W, Wang Y. Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing. Sci Rep 2017;7:40488. [PMID: 28091594 DOI: 10.1038/srep40488] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
69 Sancho-Martinez I, Izpisua Belmonte JC. Reprogramming strategies for the establishment of novel human cancer models. Cell Cycle 2016;15:2393-7. [PMID: 27314153 DOI: 10.1080/15384101.2016.1196305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
70 Kouba EJ, Eble JN, Simper N, Grignon DJ, Wang M, Zhang S, Wang L, Martignoni G, Williamson SR, Brunelli M, Luchini C, Calió A, Cheng L. High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment. Mod Pathol 2016;29:1347-57. [DOI: 10.1038/modpathol.2016.133] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
71 Dhingra P, Fu Y, Gerstein M, Khurana E. Using FunSeq2 for Coding and Non‐Coding Variant Annotation and Prioritization. Current Protocols in Bioinformatics 2017;57. [DOI: 10.1002/cpbi.23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
72 Ismail WM, Nzabarushimana E, Tang H. Algorithmic approaches to clonal reconstruction in heterogeneous cell populations. Quant Biol 2019;7:255-65. [PMID: 32431959 DOI: 10.1007/s40484-019-0188-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
73 Song J, Peng W, Wang F, Wang J. Identifying driver genes involving gene dysregulated expression, tissue-specific expression and gene-gene network. BMC Med Genomics 2019;12:168. [PMID: 31888619 DOI: 10.1186/s12920-019-0619-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
74 Juul M, Bertl J, Guo Q, Nielsen MM, Świtnicki M, Hornshøj H, Madsen T, Hobolth A, Pedersen JS. Non-coding cancer driver candidates identified with a sample- and position-specific model of the somatic mutation rate. Elife 2017;6:e21778. [PMID: 28362259 DOI: 10.7554/eLife.21778] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 5.4] [Reference Citation Analysis]
75 Stewart GL, Sage AP, Enfield KSS, Marshall EA, Cohn DE, Lam WL. Deregulation of a Cis-Acting lncRNA in Non-small Cell Lung Cancer May Control HMGA1 Expression. Front Genet 2020;11:615378. [PMID: 33505435 DOI: 10.3389/fgene.2020.615378] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Su Y, Xiang H, Xie H, Yu Y, Dong S, Yang Z, Zhao N. Application of BERT to Enable Gene Classification Based on Clinical Evidence. Biomed Res Int 2020;2020:5491963. [PMID: 33083472 DOI: 10.1155/2020/5491963] [Reference Citation Analysis]
77 da Costa VR, Araldi RP, Vigerelli H, D'Ámelio F, Mendes TB, Gonzaga V, Policíquio B, Colozza-Gama GA, Valverde CW, Kerkis I. Exosomes in the Tumor Microenvironment: From Biology to Clinical Applications. Cells 2021;10:2617. [PMID: 34685596 DOI: 10.3390/cells10102617] [Reference Citation Analysis]
78 Golonko A, Lewandowska H, Świsłocka R, Jasińska U, Priebe W, Lewandowski W. Curcumin as tyrosine kinase inhibitor in cancer treatment. European Journal of Medicinal Chemistry 2019;181:111512. [DOI: 10.1016/j.ejmech.2019.07.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
79 Belikov AV. The number of key carcinogenic events can be predicted from cancer incidence. Sci Rep 2017;7:12170. [PMID: 28939880 DOI: 10.1038/s41598-017-12448-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
80 Parida L, Haferlach C, Rhrissorrakrai K, Utro F, Levovitz C, Kern W, Nadarajah N, Twardziok S, Hutter S, Meggendorfer M, Walter W, Baer C, Haferlach T. Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA. PLoS Comput Biol 2019;15:e1007332. [PMID: 31469830 DOI: 10.1371/journal.pcbi.1007332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
81 Tan DS, Holzner M, Weng M, Srivastava Y, Jauch R. SOX17 in cellular reprogramming and cancer. Seminars in Cancer Biology 2020;67:65-73. [DOI: 10.1016/j.semcancer.2019.08.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
82 Carusillo A, Mussolino C. DNA Damage: From Threat to Treatment. Cells 2020;9:E1665. [PMID: 32664329 DOI: 10.3390/cells9071665] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
83 Oatman N, Dasgupta N, Arora P, Choi K, Gawali MV, Gupta N, Parameswaran S, Salomone J, Reisz JA, Lawler S, Furnari F, Brennan C, Wu J, Sallans L, Gudelsky G, Desai P, Gebelein B, Weirauch MT, D'Alessandro A, Komurov K, Dasgupta B. Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. Sci Adv 2021;7:eabd7459. [PMID: 33568479 DOI: 10.1126/sciadv.abd7459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
84 Heppner DE, Beyett TS, Eck MJ. A driving test for oncogenic mutations. J Biol Chem 2019;294:9390-1. [PMID: 31201242 DOI: 10.1074/jbc.H119.009452] [Reference Citation Analysis]
85 Kaina B, Izzotti A, Xu J, Christmann M, Pulliero A, Zhao X, Dobreanu M, Au WW. Inherent and toxicant-provoked reduction in DNA repair capacity: A key mechanism for personalized risk assessment, cancer prevention and intervention, and response to therapy. International Journal of Hygiene and Environmental Health 2018;221:993-1006. [DOI: 10.1016/j.ijheh.2018.07.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
86 Gao D, Mittal V, Ban Y, Lourenco AR, Yomtoubian S, Lee S. Metastatic tumor cells - genotypes and phenotypes. Front Biol (Beijing) 2018;13:277-86. [PMID: 30774650 DOI: 10.1007/s11515-018-1513-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
87 Rogers MF, Gaunt TR, Campbell C. CScape-somatic: distinguishing driver and passenger point mutations in the cancer genome. Bioinformatics 2020;36:3637-44. [PMID: 32282885 DOI: 10.1093/bioinformatics/btaa242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
88 Shibata H, Zhou L, Xu N, Egloff AM, Uppaluri R. Personalized cancer vaccination in head and neck cancer. Cancer Sci 2021;112:978-88. [PMID: 33368875 DOI: 10.1111/cas.14784] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Blair TC, Alice AF, Zebertavage L, Crittenden MR, Gough MJ. The Dynamic Entropy of Tumor Immune Infiltrates: The Impact of Recirculation, Antigen-Specific Interactions, and Retention on T Cells in Tumors. Front Oncol 2021;11:653625. [PMID: 33968757 DOI: 10.3389/fonc.2021.653625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Li M, Wang H, Liao H, Shen J, Wu Y, Wu Y, Weng Q, Zhu C, Geng X, Lan F, Xia Y, Zhang B, Zou H, Zhang N, Zhou Y, Chen Z, Shen H, Ying S, Li W. SETD8C302R Mutation Revealed from Myofibroblastoma-Discordant Monozygotic Twins Leads to p53/p21 Deficit and WEE1 Inhibitor Sensitivity. Adv Sci (Weinh) 2020;7:2001041. [PMID: 33042742 DOI: 10.1002/advs.202001041] [Reference Citation Analysis]
91 Grant AD, Vail P, Padi M, Witkiewicz AK, Knudsen ES. Interrogating Mutant Allele Expression via Customized Reference Genomes to Define Influential Cancer Mutations. Sci Rep 2019;9:12766. [PMID: 31484939 DOI: 10.1038/s41598-019-48967-8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Teimouri H, Kochugaeva MP, Kolomeisky AB. Elucidating the correlations between cancer initiation times and lifetime cancer risks. Sci Rep 2019;9:18940. [PMID: 31831779 DOI: 10.1038/s41598-019-55300-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Yamazaki T, Buqué A, Rybstein M, Chen J, Sato A, Galluzzi L. Methods to Detect Immunogenic Cell Death In Vivo. Methods Mol Biol 2020;2055:433-52. [PMID: 31502164 DOI: 10.1007/978-1-4939-9773-2_20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
94 Li X, Liu M, Ji JY. Understanding Obesity as a Risk Factor for Uterine Tumors Using Drosophila. Adv Exp Med Biol 2019;1167:129-55. [PMID: 31520353 DOI: 10.1007/978-3-030-23629-8_8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
95 Poli V, Fagnocchi L, Zippo A. Tumorigenic Cell Reprogramming and Cancer Plasticity: Interplay between Signaling, Microenvironment, and Epigenetics. Stem Cells Int 2018;2018:4598195. [PMID: 29853913 DOI: 10.1155/2018/4598195] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
96 Grillo E, Ravelli C, Corsini M, Zammataro L, Mitola S. Protein domain-based approaches for the identification and prioritization of therapeutically actionable cancer variants. Biochim Biophys Acta Rev Cancer 2021;1876:188614. [PMID: 34403770 DOI: 10.1016/j.bbcan.2021.188614] [Reference Citation Analysis]
97 Halfon MS. Perspectives on Gene Regulatory Network Evolution. Trends Genet 2017;33:436-47. [PMID: 28528721 DOI: 10.1016/j.tig.2017.04.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
98 Alsulami AF, Torres PHM, Moghul I, Arif SM, Chaplin AK, Vedithi SC, Blundell TL. COSMIC Cancer Gene Census 3D database: understanding the impacts of mutations on cancer targets. Brief Bioinform 2021:bbab220. [PMID: 34137435 DOI: 10.1093/bib/bbab220] [Reference Citation Analysis]
99 Roberts SA, Brown AJ, Wyrick JJ. Recurrent Noncoding Mutations in Skin Cancers: UV Damage Susceptibility or Repair Inhibition as Primary Driver? Bioessays 2019;41:e1800152. [PMID: 30801747 DOI: 10.1002/bies.201800152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
100 Vestergaard LK, Oliveira DNP, Høgdall CK, Høgdall EV. Next Generation Sequencing Technology in the Clinic and Its Challenges. Cancers (Basel) 2021;13:1751. [PMID: 33916923 DOI: 10.3390/cancers13081751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Linderholm A. Ancient DNA: the next generation - chapter and verse. Biol J Linn Soc 2016;117:150-60. [DOI: 10.1111/bij.12616] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
102 Terzic M, Aimagambetova G, Kunz J, Bapayeva G, Aitbayeva B, Terzic S, Laganà AS. Molecular Basis of Endometriosis and Endometrial Cancer: Current Knowledge and Future Perspectives. Int J Mol Sci 2021;22:9274. [PMID: 34502183 DOI: 10.3390/ijms22179274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Lan Y, Liu W, Zhang W, Hu J, Zhu X, Wan L, A S, Ping Y, Xiao Y. Transcriptomic heterogeneity of driver gene mutations reveals novel mutual exclusivity and improves exploration of functional associations. Cancer Med 2021;10:4977-93. [PMID: 34076361 DOI: 10.1002/cam4.4039] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA. High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival. Int J Cancer 2017;141:184-90. [PMID: 28387924 DOI: 10.1002/ijc.30726] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
105 Belikov AV, Vyatkin A, Leonov SV. The Erlang distribution approximates the age distribution of incidence of childhood and young adulthood cancers. PeerJ 2021;9:e11976. [PMID: 34434669 DOI: 10.7717/peerj.11976] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
106 Ismail WM, Tang H. Clonal reconstruction from time course genomic sequencing data. BMC Genomics 2019;20:1002. [PMID: 31888455 DOI: 10.1186/s12864-019-6328-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
107 Kotelnikova EA, Pyatnitskiy M, Paleeva A, Kremenetskaya O, Vinogradov D. Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine. Oncotarget 2016;7:52493-516. [PMID: 27191992 DOI: 10.18632/oncotarget.9370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
108 Xu B, Amallraja A, Swaminathan P, Elsey R, Davis C, Theel S, Viet S, Petersen J, Krie A, Davies G, Williams CB, Ehli E, Meißner T. Case report: 16-yr life history and genomic evolution of an ER+ HER2- breast cancer. Cold Spring Harb Mol Case Stud 2020;6:a005629. [PMID: 33008833 DOI: 10.1101/mcs.a005629] [Reference Citation Analysis]
109 Jang HJ, Lee A, Kang J, Song IH, Lee SH. Prediction of genetic alterations from gastric cancer histopathology images using a fully automated deep learning approach. World J Gastroenterol 2021; 27(44): 7687-7704 [PMID: 34908807 DOI: 10.3748/wjg.v27.i44.7687] [Reference Citation Analysis]
110 Torres M, Flórez-fernández N, Simón-vázquez R, Giménez-abián J, Díaz J, González-fernández Á, Domínguez H. Fucoidans: The importance of processing on their anti-tumoral properties. Algal Research 2020;45:101748. [DOI: 10.1016/j.algal.2019.101748] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
111 Seraj S, Cho YJ, Lee J, Ahn HJ. Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects. Biochemical Pharmacology 2020;171:113735. [DOI: 10.1016/j.bcp.2019.113735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
112 Saito S, Lin YC, Nakamura Y, Eckner R, Wuputra K, Kuo KK, Lin CS, Yokoyama KK. Potential application of cell reprogramming techniques for cancer research. Cell Mol Life Sci 2019;76:45-65. [PMID: 30283976 DOI: 10.1007/s00018-018-2924-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
113 Nussinov R, Tsai C, Jang H. Autoinhibition can identify rare driver mutations and advise pharmacology. FASEB j 2020;34:16-29. [DOI: 10.1096/fj.201901341r] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
114 Hoth M. CRAC channels, calcium, and cancer in light of the driver and passenger concept. Biochim Biophys Acta 2016;1863:1408-17. [PMID: 26705695 DOI: 10.1016/j.bbamcr.2015.12.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
115 Wuputra K, Lin CS, Tsai MH, Ku CC, Lin WH, Yang YH, Kuo KK, Yokoyama KK. Cancer cell reprogramming to identify the genes competent for generating liver cancer stem cells. Inflamm Regen 2017;37:15. [PMID: 29259714 DOI: 10.1186/s41232-017-0041-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Kroncke BM, Vanoye CG, Meiler J, George AL Jr, Sanders CR. Personalized biochemistry and biophysics. Biochemistry 2015;54:2551-9. [PMID: 25856502 DOI: 10.1021/acs.biochem.5b00189] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
117 Zhou Y, Wang S, Yan H, Pang B, Zhang X, Pang L, Wang Y, Xu J, Hu J, Lan Y, Ping Y. Identifying Key Somatic Copy Number Alterations Driving Dysregulation of Cancer Hallmarks in Lower-Grade Glioma. Front Genet 2021;12:654736. [PMID: 34163522 DOI: 10.3389/fgene.2021.654736] [Reference Citation Analysis]
118 Katigbak A, Cencic R, Robert F, Sénécha P, Scuoppo C, Pelletier J. A CRISPR/Cas9 Functional Screen Identifies Rare Tumor Suppressors. Sci Rep 2016;6:38968. [PMID: 27982060 DOI: 10.1038/srep38968] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
119 Chiara F, Indraccolo S, Trevisan A. Filling the gap between risk assessment and molecular determinants of tumor onset. Carcinogenesis 2021;42:507-16. [PMID: 33319226 DOI: 10.1093/carcin/bgaa135] [Reference Citation Analysis]
120 Mun J, Choi G, Lim B. A guide for bioinformaticians: 'omics-based drug discovery for precision oncology. Drug Discov Today 2020:S1359-6446(20)30335-4. [PMID: 32828947 DOI: 10.1016/j.drudis.2020.08.004] [Reference Citation Analysis]
121 Håvik AL, Bruland O, Myrseth E, Miletic H, Aarhus M, Knappskog PM, Lund-Johansen M. Genetic landscape of sporadic vestibular schwannoma. J Neurosurg 2018;128:911-22. [PMID: 28409725 DOI: 10.3171/2016.10.JNS161384] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
122 Cabrera-Becerril A, Vargas-De-León C, Hernández S, Miramontes P, Peralta R. Modeling the dynamics of chromosomal alteration progression in cervical cancer: A computational model. PLoS One 2017;12:e0180882. [PMID: 28723940 DOI: 10.1371/journal.pone.0180882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
123 Sommer G, Heise T. Role of the RNA-binding protein La in cancer pathobiology. RNA Biol 2021;18:218-36. [PMID: 32687431 DOI: 10.1080/15476286.2020.1792677] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
124 Deng Y, Luo S, Zhang X, Zou C, Yuan H, Liao G, Xu L, Deng C, Lan Y, Zhao T, Gao X, Xiao Y, Li X. A pan-cancer atlas of cancer hallmark-associated candidate driver lncRNAs. Mol Oncol 2018;12:1980-2005. [PMID: 30216655 DOI: 10.1002/1878-0261.12381] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
125 Raimondi D, Passemiers A, Fariselli P, Moreau Y. Current cancer driver variant predictors learn to recognize driver genes instead of functional variants. BMC Biol 2021;19:3. [PMID: 33441128 DOI: 10.1186/s12915-020-00930-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
126 Tegally H, Kensler KH, Mungloo-Dilmohamud Z, Ghoorah AW, Rebbeck TR, Baichoo S. Discovering novel driver mutations from pan-cancer analysis of mutational and gene expression profiles. PLoS One 2020;15:e0242780. [PMID: 33232371 DOI: 10.1371/journal.pone.0242780] [Reference Citation Analysis]
127 Iranzo J, Martincorena I, Koonin EV. Cancer-mutation network and the number and specificity of driver mutations. Proc Natl Acad Sci U S A 2018;115:E6010-9. [PMID: 29895694 DOI: 10.1073/pnas.1803155115] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
128 Xia W, Xie W. Rebooting the Epigenomes during Mammalian Early Embryogenesis. Stem Cell Reports 2020;15:1158-75. [PMID: 33035464 DOI: 10.1016/j.stemcr.2020.09.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
129 Lyra DH, Griffiths CA, Watson A, Joynson R, Molero G, Igna AA, Hassani-Pak K, Reynolds MP, Hall A, Paul MJ. Gene-based mapping of trehalose biosynthetic pathway genes reveals association with source- and sink-related yield traits in a spring wheat panel. Food Energy Secur 2021;10:e292. [PMID: 34594548 DOI: 10.1002/fes3.292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Lambrughi M, Tiberti M, Allega MF, Sora V, Nygaard M, Toth A, Salamanca Viloria J, Bignon E, Papaleo E. Analyzing Biomolecular Ensembles. Methods Mol Biol 2019;2022:415-51. [PMID: 31396914 DOI: 10.1007/978-1-4939-9608-7_18] [Reference Citation Analysis]
131 Zaporozhchenko IA, Ponomaryova AA, Rykova EY, Laktionov PP. The potential of circulating cell-free RNA as a cancer biomarker: challenges and opportunities. Expert Review of Molecular Diagnostics 2017;18:133-45. [DOI: 10.1080/14737159.2018.1425143] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 9.5] [Reference Citation Analysis]
132 Gorlov IP, Pikielny CW, Frost HR, Her SC, Cole MD, Strohbehn SD, Wallace-Bradley D, Kimmel M, Gorlova OY, Amos CI. Gene characteristics predicting missense, nonsense and frameshift mutations in tumor samples. BMC Bioinformatics 2018;19:430. [PMID: 30453881 DOI: 10.1186/s12859-018-2455-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]